TGF-β, to target or not to target; to prevent thyroid cancer progression?

Isha Karnik; Rachel Sutherland; Joanna Elson; Sebastian Aspinall; Annette Meeson

doi:10.1016/j.bbcan.2022.188752

TGF-β, to target or not to target; to prevent thyroid cancer progression?

Biochim Biophys Acta Rev Cancer. 2022 Jul;1877(4):188752. doi: 10.1016/j.bbcan.2022.188752. Epub 2022 Jun 18.

Authors

Isha Karnik¹, Rachel Sutherland¹, Joanna Elson¹, Sebastian Aspinall², Annette Meeson³

Affiliations

¹ Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle Upon Tyne, UK.
² Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle Upon Tyne, UK; Department of General Surgery, Aberdeen Royal Infirmary, Aberdeen, UK.
³ Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle Upon Tyne, UK. Electronic address: Annette.Meeson@ncl.ac.uk.

PMID: 35728736
DOI: 10.1016/j.bbcan.2022.188752

Abstract

Thyroid cancer (TC) is a common endocrine cancer with a rising incidence. Current treatment fails to eliminate aggressive thyroid tumours, prompting an investigation into the processes that cause disease progression. In this review, we provide insight into TGF-β driven epithelial to mesenchymal transition (EMT), summarizing the current literature surrounding thyroid carcinogenesis, and discuss the potential for therapeutic strategies targeting the TGF-β signalling pathway. Understanding the underlying mechanisms that regulate cancer stem cell (CSC) growth and TGF-β signalling may provide novel therapeutic approaches for highly resistant TCs.

Keywords: Epithelial to mesenchymal transition; Thyroid cancer; Transforming growth factor beta.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Epithelial-Mesenchymal Transition / physiology
Humans
Signal Transduction
Thyroid Neoplasms* / genetics
Transforming Growth Factor beta* / metabolism

Substances

Transforming Growth Factor beta